File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation

TitleLongitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation
Authors
KeywordsChildhood
Survivor
Haematopoietic stem cell transplantation
Allogeneic
Immunization
Issue Date2012
Citation
British Journal of Haematology, 2012, v. 156, n. 1, p. 109-117 How to Cite?
AbstractThe long-term antibody responses to re-immunization in recipients of allogeneic haematopoietic stem cell transplantation (allo-HSCT) have not been well studied. We prospectively and longitudinally evaluated the antibody responses to eight vaccine antigens (diphtheria, tetanus, pertussis, measles, mumps, rubella, hepatitis B, and poliovirus) and assessed the factors associated with negative titres in 210 allo-HSCT recipients at St. Jude Children's Research Hospital. Antibody responses lasting for more than 5years after immunization were observed in most patients for tetanus (95·7%), rubella (92·3%), poliovirus (97·9%), and, in diphtheria-tetanus-acellular pertussis (DTaP) recipients, diphtheria (100%). However, responses to pertussis (25·0%), measles (66·7%), mumps (61·5%), hepatitis B (72·9%), and diphtheria in tetanus-diphtheria (Td) recipients (48·6%) were less favourable, with either only transient antibody responses or persistently negative titres. Factors associated with vaccine failure were older age at immunization; lower CD3, CD4 or CD19 counts; higher IgM concentrations; positive recipient cytomegalovirus serology; negative titres before immunization; acute or chronic graft-versus-host disease; and radiation during preconditioning. These response patterns and clinical factors can be used to formulate re-immunization and monitoring strategies. Patients at risk for vaccine failure should have long-term follow-up; those with loss of antibody response or no seroconversion should receive booster immunizations. © 2011 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/294448
ISSN
2020 Impact Factor: 6.998
2015 SCImago Journal Rankings: 2.313
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorInaba, Hiroto-
dc.contributor.authorHartford, Christine M.-
dc.contributor.authorPei, Deqing-
dc.contributor.authorPosner, Meredith J.-
dc.contributor.authorYang, Jie-
dc.contributor.authorHayden, Randall T.-
dc.contributor.authorSrinivasan, Ashok-
dc.contributor.authorTriplett, Brandon M.-
dc.contributor.authorMcCulllers, Jon A.-
dc.contributor.authorPui, Ching Hon-
dc.contributor.authorLeung, Wing-
dc.date.accessioned2020-12-03T08:22:45Z-
dc.date.available2020-12-03T08:22:45Z-
dc.date.issued2012-
dc.identifier.citationBritish Journal of Haematology, 2012, v. 156, n. 1, p. 109-117-
dc.identifier.issn0007-1048-
dc.identifier.urihttp://hdl.handle.net/10722/294448-
dc.description.abstractThe long-term antibody responses to re-immunization in recipients of allogeneic haematopoietic stem cell transplantation (allo-HSCT) have not been well studied. We prospectively and longitudinally evaluated the antibody responses to eight vaccine antigens (diphtheria, tetanus, pertussis, measles, mumps, rubella, hepatitis B, and poliovirus) and assessed the factors associated with negative titres in 210 allo-HSCT recipients at St. Jude Children's Research Hospital. Antibody responses lasting for more than 5years after immunization were observed in most patients for tetanus (95·7%), rubella (92·3%), poliovirus (97·9%), and, in diphtheria-tetanus-acellular pertussis (DTaP) recipients, diphtheria (100%). However, responses to pertussis (25·0%), measles (66·7%), mumps (61·5%), hepatitis B (72·9%), and diphtheria in tetanus-diphtheria (Td) recipients (48·6%) were less favourable, with either only transient antibody responses or persistently negative titres. Factors associated with vaccine failure were older age at immunization; lower CD3, CD4 or CD19 counts; higher IgM concentrations; positive recipient cytomegalovirus serology; negative titres before immunization; acute or chronic graft-versus-host disease; and radiation during preconditioning. These response patterns and clinical factors can be used to formulate re-immunization and monitoring strategies. Patients at risk for vaccine failure should have long-term follow-up; those with loss of antibody response or no seroconversion should receive booster immunizations. © 2011 Blackwell Publishing Ltd.-
dc.languageeng-
dc.relation.ispartofBritish Journal of Haematology-
dc.subjectChildhood-
dc.subjectSurvivor-
dc.subjectHaematopoietic stem cell transplantation-
dc.subjectAllogeneic-
dc.subjectImmunization-
dc.titleLongitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1365-2141.2011.08913.x-
dc.identifier.pmid22017512-
dc.identifier.pmcidPMC3237834-
dc.identifier.scopuseid_2-s2.0-83555165050-
dc.identifier.volume156-
dc.identifier.issue1-
dc.identifier.spage109-
dc.identifier.epage117-
dc.identifier.eissn1365-2141-
dc.identifier.isiWOS:000298058100012-
dc.identifier.issnl0007-1048-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats